CSL doubles manufacturing capacity

CSLBiotherapies.jpg

CSL Biotherapies, a subsidiary of CSL Limited Australia and one of the world’s leading manufacturers of influenza vaccine, has announced it has been awarded a contract by the United States Department of Health Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

CSL Limited, in Melbourne, Australia, has invested US $80 million to double the company’s influenza manufacturing capacity to 40 million trivalent influenza vaccine doses per season, making it one of the largest influenza facilities for global markets.

“We are very pleased to again be working with the U.S. Government on its pandemic preparedness efforts,” Dr. John Anderson, senior vice president of CSL Biotherapies, said.

He went on to say “we are proud to contribute our 45 years of successful influenza vaccine manufacturing experience to the U.S. national strategy for pandemic influenza”.

The CSL group employs more than 11,000 people and operates in 27 countries worldwide.